Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511184 · ClinicalTrials.gov registry record · Phase 1
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02511184 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 9 participants.
The verdict
NCT02511184, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.
Interventions
- DRUG Pembrolizumab
- DRUG Crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511184
The ClinicalTrials.gov registry entry for NCT02511184 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02511184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02511184 about?
NCT02511184 is a clinical study titled "Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients". The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.
What is the current status of trial NCT02511184?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-10. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02511184?
The interventions under investigation include: Pembrolizumab (DRUG), Crizotinib (DRUG).
Who is sponsoring clinical trial NCT02511184?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.